Iowa House Bill HF2438

Iowa 2025-2026 Regular Session

• Introduced: 2/12/26
• Refer: 2/12/26

Caption

A bill for an act relating to health carriers and payment of claims, audits, and standards of conduct; prior authorizations and utilization review organizations; and providing civil penalties and including applicability provisions.(See HF 2635.)

Impact

The bill sets forth a structured protocol for audits associated with clean claims, requiring carriers to reimburse providers for reasonable administrative costs incurred in response to audits. It outlines the responsibilities for health carriers during the audit process, such as timely notifications and decisions, while imposing civil penalties for violations. These protections are expected to improve the financial certainty for health care providers and lead to more transparent interactions between providers and health insurers. Particularly, the ability to appeal adverse audit determinations is a crucial new addition that enhances provider rights.

Summary

House File 2438 introduces significant amendments relevant to health carriers, focusing on the payment of claims, audits, prior authorizations, and the standards of conduct for these organizations. The bill mandates that health carriers either accept and pay or deny a clean claim within defined time frames—30 days for electronic submissions and 45 days for paper claims. Specifically, after paying a clean claim, carriers cannot retroactively deny, reduce, or recoup payment, except in cases of fraud or misrepresentation. This approach aims to protect health care providers from undue financial losses and streamline the claims process.

Contention

A notable feature of HF2438 is the stringent provisions around prior authorization practices. The bill restricts health carriers and utilization review organizations from denying or downgrading prior authorization requests unless a qualified reviewer—practicing in the same specialty as the requesting provider—makes such determinations. This stipulation aims to ensure that the evaluations are clinically appropriate and fair, addressing previous concerns regarding the lack of specialty-specific oversight in authorization decisions. Potential contention could arise from insurance companies arguing that strict regulations might limit their flexibility to manage costs effectively.